NurExone Biologic Inc: NurExone Biologic Secures EMA Orphan Status for ExoPTEN in Spinal Cord Injury, Accelerating Pathway to European Markets
NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (Germany: J90) ("NurExone" or the "Company"), a biopharmaceutical company developing exosome-based ...
The curse of Band Aid: As charity single celebrates its 40th anniversary, how the lives of the original line-up have been plagued by tragedy
Band Aid's 1984 single never fails to dominate the UK radio waves every December - serving as a reminder of the tragedies ...
NurExone Biologic Secures EMA Orphan Status for ExoPTEN in Spinal Cord Injury, Accelerating Pathway to European Markets
NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (Germany: J90) (" NurExone " or the " Company "), a biopharmaceutical company developing exosome-based regenerative therapies, is pleased to announce ...
Minimally invasive neural interface allows brain access without skull opening
A team of researchers led by Rice University's Jacob Robinson and the University of Texas Medical Branch's Peter Kan has ...
Sexual health restoration after spinal cord injury possible: Expert
Experts are making significant advancements in restoring sexual health and other bodily functions for spinal cord injury ...